Search Results

, clinical options are limited, and the median overall survival for patients with chRCC treated with targeted drugs ranges between 25 and 32 months. 1 – 3 The rapamycin analogs everolimus and temsirolimus are effective anticancer drugs that inhibit mTOR

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 24 Dutcher JP Szczylik C Tannir N . Correlation of survival with tumor histology, age, and prognostic risk group for previously

mTOR Inhibitors Key Points Four mTOR inhibitors are available for clinical trials: rapamycin and 3 derivatives: temsirolimus, everolimus, and deforolimus. All 4 drugs are structurally similar; differences are related to route of administration and

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors Principal

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or

scientific peer-review process and are overseen by the ORP. Several NCCN sponsored-studies funded through the grant mechanism are highlighted below. Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology in Men with Castration

rapamycin and its analogues everolimus and temsirolimus, which allosterically inhibit mTORC1 only, and mTOR kinase inhibitors, which inhibit both mTORC1 and mTORC2. 41 Because rapamycin's discovery and clinical use actually preceded the identification of

of cell growth . Cell 2000 ; 103 : 253 – 262 . 47 Hudes G Carducci M Tomczak P . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 48 Motzer RJ Escudier B